SABS - EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidate | Benzinga
SAB Biotherapeutics (NASDAQ: SABS) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferred stock in a private placement of up to $130 million in gross proceeds.
The full proceeds, when funded, are expected to fund the company through 2026 and topline Phase 2 results.
The transaction is led by RA Capital Management, with participation from ...